

Bart van Hoek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/730938/publications.pdf>

Version: 2024-02-01

152
papers

10,278
citations

81900

39
h-index

34986

98
g-index

153
all docs

153
docs citations

153
times ranked

10468
citing authors

#	ARTICLE	IF	CITATIONS
1	Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1776-1783.e4.	4.4	11
2	A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation. <i>Journal of Hepatology</i> , 2022, 76, 371-382.	3.7	54
3	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
4	Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	1.4	1
5	Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study. <i>European Journal of Internal Medicine</i> , 2022, 97, 56-61.	2.2	1
6	B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. <i>JHEP Reports</i> , 2022, 4, 100460.	4.9	5
7	Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region. <i>American Journal of Transplantation</i> , 2021, 21, 229-240.	4.7	37
8	Donor diabetes mellitus is a risk factor for diminished outcome after liver transplantation: a nationwide retrospective cohort study. <i>Transplant International</i> , 2021, 34, 110-117.	1.6	4
9	The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 475-476.	3.7	4
10	Refitting the Model for End-stage Liver Disease for the Eurotransplant Region. <i>Hepatology</i> , 2021, 74, 351-363.	7.3	10
11	Invited response to "MELD calibration". <i>American Journal of Transplantation</i> , 2021, 21, 440-441.	4.7	1
12	Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab006.	0.9	5
13	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. <i>Hepatology International</i> , 2021, 15, 510-519.	4.2	14
14	Both muscle quantity and quality are predictors of waiting list mortality in patients with end-stage liver disease. <i>Clinical Nutrition ESPEN</i> , 2021, 42, 272-279.	1.2	15
15	Hypothermic Machine Perfusion in Liver Transplantation " A Randomized Trial. <i>New England Journal of Medicine</i> , 2021, 384, 1391-1401.	27.0	305
16	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4262-4272.	2.4	8
17	Recurrence of primary sclerosing cholangitis after liver transplantation " analysing the European Liver Transplant Registry and beyond. <i>Transplant International</i> , 2021, 34, 1455-1467.	1.6	23
18	Joint modeling of liver transplant candidates outperforms the model for end-stage liver disease: The effect of disease development over time on patient outcome. <i>American Journal of Transplantation</i> , 2021, 21, 3583-3592.	4.7	5

#	ARTICLE	IF	CITATIONS
19	Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1. <i>United European Gastroenterology Journal</i> , 2021, 9, 662-671.	3.8	10
20	Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure. <i>JHEP Reports</i> , 2021, 3, 100369.	4.9	5
21	The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. <i>Journal of Clinical Medicine</i> , 2021, 10, 4562.	2.4	9
22	Budget impact of optimizing rifaximin use for the prevention of recurrent hepatic encephalopathy in The Netherlands. <i>Journal of Medical Economics</i> , 2021, 24, 1149-1163.	2.1	2
23	Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis. <i>Cells</i> , 2021, 10, 3325.	4.1	2
24	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1609-1617.e4.	4.4	25
25	Liver retransplantation in adult recipients: analysis of a 38-year experience in the Netherlands. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 26-33.	2.6	10
26	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. <i>Annals of Surgery</i> , 2020, 272, 855-862.	4.2	85
27	Early Predictors of Short-Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis. <i>Liver Transplantation</i> , 2020, 26, 1573-1581.	2.4	11
28	Evaluation of Liver Graft Donation After Euthanasia. <i>JAMA Surgery</i> , 2020, 155, 917.	4.3	21
29	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020, 40, 2164-2171.	3.9	16
30	Screening for abnormal glycosylation in a cohort of adult liver disease patients. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1310-1320.	3.6	6
31	Donor hepatectomy time influences ischemia-reperfusion injury of the biliary tree in donation after circulatory death liver transplantation. <i>Surgery</i> , 2020, 168, 160-166.	1.9	15
32	Selected liver grafts from donation after circulatory death can be safely used for retransplantation – a multicenter retrospective study. <i>Transplant International</i> , 2020, 33, 667-674.	1.6	4
33	Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantation recipients with ulcerative colitis?. <i>Digestive and Liver Disease</i> , 2020, 52, 528-533.	0.9	3
34	The role of complement activation in autoimmune liver disease. <i>Autoimmunity Reviews</i> , 2020, 19, 102534.	5.8	15
35	Editorial: genome-wide association studies for developing chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1083-1084.	3.7	1
36	Prognostic Importance of Increased Right Ventricular Afterload in Orthotopic Liver Transplantation Recipients With Endstage Cirrhosis. <i>Heart Lung and Circulation</i> , 2019, 28, 893-900.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Comment on "The role of graft reperfusion sequence in the development of non-anastomotic biliary strictures following orthotopic liver transplantation: A meta-analysis" Hepatobiliary and Pancreatic Diseases International, 2019, 18, 401.	1.3	0
38	Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers. Journal of Cellular and Molecular Medicine, 2019, 23, 6238-6250.	3.6	18
39	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical Genitourinary Cancer, 2019, 17, e893-e896.	1.9	0
40	Impact of Temporary Portocaval Shunting and Initial Arterial Reperfusion in Orthotopic Liver Transplantation. Liver Transplantation, 2019, 25, 1690-1699.	2.4	6
41	Adverse events related to low dose corticosteroids in autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 1120-1126.	3.7	42
42	Study protocol for a multicenter randomized controlled trial to compare the efficacy of end-ischemic dual hypothermic oxygenated machine perfusion with static cold storage in preventing non-anastomotic biliary strictures after transplantation of liver grafts donated after circulatory death: DHOPE-DCD trial. BMC Gastroenterology, 2019, 19, 40.	2.0	36
43	Outcome of Liver Transplant Patients With High Urgent Priority: Are We Doing the Right Thing?. Transplantation, 2019, 103, 1181-1190.	1.0	14
44	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2068-2075.e2.	4.4	55
45	Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 636-643.	3.7	64
46	Predictive Capacity of Risk Models in Liver Transplantation. Transplantation Direct, 2019, 5, e457.	1.6	18
47	Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 940-947.e2.	4.4	36
48	The role of proportionate kinetic growth rate fraction in future remnant liver function over volume determined by 99mTc-Mebrofenin hepatobiliary scintigraphy including SPECT and computed tomography in the risk prediction of postoperative mortality in ALPPS. Surgery, 2019, 165, 1244-1245.	1.9	0
49	Optimizing the Use of Geriatric Livers for Transplantation in the Eurotransplant Region. Liver Transplantation, 2019, 25, 260-274.	2.4	11
50	8 weeks of sofosbuvir/ledipasvir is effective in DAA-naïve non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 2019, 70, 554-557.	3.7	4
51	Utilizing Mechanistic Biomarkers in Treating Paracetamol Hepatotoxicity. Hepatology, 2018, 68, 2032-2035.	7.3	0
52	CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Journal of Pathology, 2018, 245, 297-310.	4.5	25
53	The center effect in liver transplantation in the Eurotransplant region: a retrospective database analysis. Transplant International, 2018, 31, 610-619.	1.6	10
54	Use of thrombolytic therapy in DCD liver transplantation does not seem to improve outcome. American Journal of Transplantation, 2018, 18, 1029.	4.7	4

#	ARTICLE	IF	CITATIONS
55	Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13163.	1.6	17
56	Trajectories of Anxiety and Depression After Liver Transplantation as Related to Outcomes During 2-Year Follow-Up: A Prospective Cohort Study. <i>Psychosomatic Medicine</i> , 2018, 80, 174-183.	2.0	36
57	Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study. <i>Transplant International</i> , 2018, 31, 590-599.	1.6	9
58	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	12.1	42
59	Identification and Validation of the Predictive Capacity of Risk Factors and Models in Liver Transplantation Over Time. <i>Transplantation Direct</i> , 2018, 4, e382.	1.6	13
60	Mesenchymal stromal cells prevent progression of liver fibrosis in a novel zebrafish embryo model. <i>Scientific Reports</i> , 2018, 8, 16005.	3.3	17
61	Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates. <i>Clinical Transplantation</i> , 2018, 32, e13412.	1.6	9
62	Role of age in presentation, response to therapy and outcome of autoimmune hepatitis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e165.	2.5	19
63	A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. <i>Journal of Hepatology</i> , 2018, 68, 707-714.	3.7	161
64	A prospective cohort study on posttraumatic stress disorder in liver transplantation recipients before and after transplantation: Prevalence, symptom occurrence, and intrusive memories. <i>Journal of Psychosomatic Research</i> , 2017, 95, 88-93.	2.6	20
65	Hemodynamic response to primary prophylactic therapy with nonselective β -blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 380-387.	1.6	12
66	Trajectories of anxiety and depression in liver transplant candidates during the waiting list period. <i>British Journal of Health Psychology</i> , 2017, 22, 481-501.	3.5	21
67	Short article. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 535-538.	1.6	0
68	Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2017, 32, 459-467.	2.2	9
69	Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. <i>Critical Care</i> , 2017, 21, 321.	5.8	19
70	Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β -blocker for prevention of variceal rebleeding. <i>Hepatology</i> , 2016, 63, 581-589.	7.3	168
71	Flushing the liver with urokinase before transplantation does not prevent nonanastomotic biliary strictures. <i>Liver Transplantation</i> , 2016, 22, 420-426.	2.4	13
72	Copeptin is an independent prognostic factor for transplant-free survival in cirrhosis. <i>Liver International</i> , 2016, 36, 530-537.	3.9	12

#	ARTICLE	IF	CITATIONS
73	Auxiliary or orthotopic liver transplantation for acute fatty liver of pregnancy: case series and review of the literature. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 1394-1398.	2.3	13
74	Longterm results of liver transplantation from donation after circulatory death. <i>Liver Transplantation</i> , 2016, 22, 1107-1114.	2.4	71
75	Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. <i>Drug Safety</i> , 2016, 39, 589-611.	3.2	67
76	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 914-920.	3.7	35
77	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	1.0	339
78	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 685-697.	9.1	402
79	Effects of preventive versus on-demand nutritional support on paid labour productivity, physical exercise and performance status during PEG-interferon-containing treatment for hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 221-229.	1.5	1
80	Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0161821.	2.5	8
81	Value of Magnetic Resonance Cholangiopancreatography in Assessment of Nonanastomotic Biliary Strictures After Liver Transplantation. <i>Transplantation Direct</i> , 2015, 1, e42.	1.6	11
82	Combined effect of donor and recipient risk on outcome after liver transplantation: Research of the Eurotransplant database. <i>Liver Transplantation</i> , 2015, 21, 1486-1493.	2.4	31
83	Elderly donor liver grafts are not associated with a higher incidence of biliary complications after liver transplantation: results of a national multicenter study. <i>Clinical Transplantation</i> , 2015, 29, 636-643.	1.6	8
84	Biliary Complications After Liver Transplantation From Donation After Cardiac Death Donors. <i>Annals of Surgery</i> , 2015, 261, e64.	4.2	15
85	Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138264.	2.5	15
86	Gastric Variceal Hemorrhage in a Noncirrhotic Patient Treated with Balloon-Occluded Retrograde Transvenous Obliteration. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 1060-1063.	2.0	0
87	High peak alanine aminotransferase determines extra risk for nonanastomotic biliary strictures after liver transplantation with donation after circulatory death. <i>Transplant International</i> , 2015, 28, 492-501.	1.6	25
88	No Association Between BMD and Prevalent Vertebral Fractures in Liver Transplant Recipients at Time of Screening Before Transplantation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3677-3685.	3.6	17
89	<scp>MMP</scp> is a disease-modifying gene in primary sclerosing cholangitis. <i>Liver International</i> , 2014, 34, 274-280.	3.9	11
90	Longitudinal Changes in BMD and Fracture Risk in Orthotopic Liver Transplant Recipients Not Using Bone-Modifying Treatment. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1763-1769.	2.8	30

#	ARTICLE	IF	CITATIONS
91	Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 141-147.	2.0	19
92	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. <i>Gastroenterology</i> , 2014, 147, 443-452.e5.	1.3	268
93	Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1245-1254.	1.5	153
94	Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. <i>Journal of Hepatology</i> , 2013, 58, 141-147.	3.7	182
95	The price of donation after cardiac death in liver transplantation: a prospective cost-effectiveness study. <i>Transplant International</i> , 2013, 26, 411-418.	1.6	30
96	Cytotoxic T Lymphocyte Antigen-4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. <i>Liver International</i> , 2013, 33, 1039-1043.	3.9	15
97	Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. <i>Hepatology</i> , 2013, 58, 2045-2055.	7.3	519
98	Recipient's Genetic R702W NOD2 Variant Is Associated with an Increased Risk of Bacterial Infections after Orthotopic Liver Transplantation. <i>PLoS ONE</i> , 2013, 8, e72617.	2.5	3
99	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	3.7	49
100	Preventive versus on-demand nutritional support during antiviral treatment for hepatitis C: A randomized controlled trial. <i>Journal of Hepatology</i> , 2012, 57, 1069-1075.	3.7	10
101	Risk factors for infection after liver transplantation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 61-72.	2.4	58
102	Transarterial Radioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 144.	1.6	27
103	Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 635-642.	9.1	38
104	Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. <i>European Journal of Clinical Investigation</i> , 2012, 42, 760-767.	3.4	46
105	Sequential Liver Chemistry Profiling and Abdominal Ultrasound Assessments to Predict Biliary Strictures after Liver Transplantation. <i>The Open Transplantation Journal</i> , 2012, 6, 1-5.	0.1	0
106	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	27.0	1,466
107	Mannose-binding lectin and Ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. <i>Journal of Hepatology</i> , 2011, 55, 800-807.	3.7	38
108	Protein energy malnutrition predicts complications in liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 982-989.	1.6	170

#	ARTICLE	IF	CITATIONS
109	Use of a liver from donor after cardiac death: is it appropriate for the sick or the stable?. <i>Current Opinion in Organ Transplantation</i> , 2011, 16, 239-242.	1.6	13
110	Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. <i>Liver International</i> , 2011, 31, 92-98.	3.9	117
111	Chewing khat and chronic liver disease. <i>Liver International</i> , 2011, 31, 434-436.	3.9	24
112	Matrix metalloproteinase 2 genotype is associated with nonanastomotic biliary strictures after orthotopic liver transplantation. <i>Liver International</i> , 2011, 31, 1110-1117.	3.9	18
113	Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates. <i>Liver Transplantation</i> , 2011, 17, 261-269.	2.4	17
114	Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy?. <i>Gastroenterology Research and Practice</i> , 2011, 2011, 1-4.	1.5	16
115	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 190.	2.6	146
116	Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation. <i>Hepatology</i> , 2010, 52, 1100-1110.	7.3	61
117	Similar liver transplantation survival with selected cardiac death donors and brain death donors. <i>British Journal of Surgery</i> , 2010, 97, 744-753.	0.3	189
118	Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. <i>BMC Gastroenterology</i> , 2010, 10, 144.	2.0	34
119	No beneficial effects of amantadine in treatment of chronic hepatitis C patients. <i>Digestive and Liver Disease</i> , 2010, 42, 496-502.	0.9	18
120	Antineutrophil Cytoplasmic Antibodies in Small-Duct Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2009, 136, 364.	1.3	4
121	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , 2009, 10, 35-43.	10.7	1,920
122	Transjugular Intrahepatic Portosystemic Shunt in Patients With Chronic Portal Vein Occlusion and Cavernous Transformation. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 982-984.	2.2	41
123	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	1.0	64
124	Flexible Limited Sampling Model for Monitoring Tacrolimus in Stable Patients Having Undergone Liver Transplantation With Samples 4 to 6 Hours After Dosing Is Superior to Trough Concentration. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 456-461.	2.0	17
125	?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?2b in chronic hepatitis C non-responders. <i>Liver International</i> , 2007, 27, 070816165951003-???	3.9	30
126	Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 97, 181-185.	3.4	26

#	ARTICLE	IF	CITATIONS
127	Preanalytical Conditions and Circulating Matrix Metalloproteinases. <i>Transplantation</i> , 2005, 79, 745-746.	1.0	9
128	Hepato-biliary and Pancreatic Function. , 2005, , 247-283.		0
129	Mannose Binding Lectin Gene Polymorphisms Confer a Major Risk for Severe Infections After Liver Transplantation. <i>Gastroenterology</i> , 2005, 129, 408-414.	1.3	125
130	Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. <i>Thrombosis and Haemostasis</i> , 2004, 91, 506-513.	3.4	47
131	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. <i>Hepatology</i> , 2004, 39, 500-508.	7.3	315
132	Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. <i>Liver Transplantation</i> , 2004, 10, 183-189.	2.4	16
133	ASSESSMENT OF SERUM MATRIX METALLOPROTEINASES MMP-2 AND MMP-9 AFTER HUMAN LIVER TRANSPLANTATION: INCREASED SERUM MMP-9 LEVEL IN ACUTE REJECTION. <i>Transplantation</i> , 2004, 77, 1646-1652.	1.0	39
134	Extensive chimerism in liver transplants: Vascular endothelium, bile duct epithelium, and hepatocytes. <i>Liver Transplantation</i> , 2003, 9, 552-556.	2.4	77
135	Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. <i>Thrombosis and Haemostasis</i> , 2003, 89, 718-725.	3.4	48
136	The Potentiating Effect of Ribavirin on Interferon in the Treatment of Hepatitis C: Lack of Evidence for Ribavirin-Induced Viral Mutagenesis. <i>Antiviral Therapy</i> , 2003, 8, 535-540.	1.0	16
137	The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2001, 35, 338-343.	3.7	92
138	SUCCESSFUL OUTCOME WITH A QUINTUPLE APPROACH OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER. <i>Transplantation</i> , 2001, 71, 47-52.	1.0	39
139	Severe hepatitis and pure red cell aplasia in adult Still's disease: good response to immunosuppressive therapy. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1639-1642.	2.3	16
140	Auxiliary versus orthotopic liver transplantation for acute liver failure. <i>Journal of Hepatology</i> , 1999, 30, 699-705.	3.7	157
141	Liver Rupture after Transcatheter Arterial Chemoembolization of a Giant Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 1999, 10, 895-897.	0.5	7
142	Graves' hyperthyroidism in a patient with primary sclerosing cholangitis. Coincidence or combined pathogenesis?. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 269-272.	1.6	18
143	<i>Campylobacter jejuni</i> peritonitis in a patient with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 1219-1221.	1.6	13
144	LONG-TERM TREATMENT OF RECURRENT PERIHILAR NONANASTOMATIC BILIARY STRICTURES AFTER LIVER TRANSPLANTATION WITH EXPANDABLE METALLIC STENTS. <i>Transplantation</i> , 1995, 60, 399-400.	1.0	1

#	ARTICLE	IF	CITATIONS
145	Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion. CardioVascular and Interventional Radiology, 1995, 18, 192-195.	2.0	27
146	Temporary heterotopic auxiliary liver transplantation for fulminant hepatitis B. Journal of Hepatology, 1995, 23, 109-118.	3.7	23
147	Hepatic Allograft Rejection: New Developments in Terminology, Diagnosis, Prevention, and Treatment. Mayo Clinic Proceedings, 1993, 68, 69-79.	3.0	84
148	Severe Ductopenic Rejection Following Liver Transplantation: Incidence, Time of Onset, Risk Factors, Treatment, and Outcome. Seminars in Liver Disease, 1992, 12, 41-50.	3.6	76
149	Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology, 1992, 15, 215-221.	7.3	187
150	Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology, 1991, 14, 721-729.	7.3	156
151	Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology, 1991, 14, 721-729.	7.3	34
152	The immunology of hepatic allograft rejection. Clinical Immunology Newsletter, 1990, 10, 69-73.	0.1	2